CYPARK – Fundamental Analysis (31 Mar 2015)

CYPARK Analysis:-

Excel –

Notes –

My View:-

  • Fair value:
    • Absolute EY%
      • Trailing:
        • FY14 (EPS: 0.208) – Fair value 2.56 (Fair Value Uncertainty: MEDIUM)
        • R4Q (EPS: 0.199) – Fair value 2.45 (Fair Value Uncertainty: MEDIUM)
      • Forward:
        • FY15 (EPS: 0.35) – Fair value 4.3 (Fair Value Uncertainty: LOW)
        • FY16 (EPS: 0.36) – Fair value 4.43 (Fair Value Uncertainty: LOW)
      • EPS applied to reach the current stock price (1.79): 0.146
  • CYPARK’s valuation looks very attractive.
  • This stock will stay in the Watch List. I may buy CYPARK in near future.

Latest Financial – Q1 2015 Financial Report (31 Mar 2015)

At the time of writing, I did not own shares of CYPARK.


One thought on “CYPARK – Fundamental Analysis (31 Mar 2015)

  1. LC,
    Thank you for the analysis. I found the notes to very beneficial.
    Many companies are venturing into the RE business to generate their own power source to ensure long term savings. In addition to the pharma sector the above business is another growth driver.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s